Segregation for leaf trichome density was noticed in a cold-hardy hybrid grape inhabitants GE1025 (N = ∼125, MN1264 × MN1246) that was beforehand used to detect a quantitative trait locus (QTL) underlying foliar phylloxera resistance on chromosome 14. Our speculation was that prime trichome density was related to resistance to phylloxera. Existing literature discovered trichome density QTL on chromosomes 1 and 15 utilizing a hybrid grape inhabitants of “Horizon” × Illinois 547-1 and steered a few candidate genes. To validate the reported QTL and our speculation, interval mapping was performed in GE1025 with earlier genotyping-by-sequencing (GBS) single nucleotide polymorphism (SNP) genotype knowledge and phenotypic scores collected utilizing a 0-6 trichome density scale at a number of leaf positions.
Evaluations had been carried out on replicated pressured dormant cuttings in 2 years and on field-grown leaves in 1 12 months. There was no robust relationship between trichome density and phylloxera resistance aside from a Pearson’s correlation (r) of about -0.2 between a few trichome density traits and phylloxera severity traits at 2 and three weeks after infestation. Two genetic areas had been repeatedly detected for a number of trichome density traits: from 10 to 20.7 Mbp (∼10 Mbp) on chromosome 1 for ribbon and easy density traits and from 2.four to eight.9 Mbp on chromosome 10 for ribbon density traits, explaining 12.1-48.2 and 12.6-27.5% of phenotypic variation, respectively.
To high-quality map, we genotyped a bigger inhabitants, GE1783 (N = ∼1,023, MN1264 × MN1246), with conserved rhAmpSeq haplotype markers throughout a number of Vitis species and phenotyped 233 chosen potential recombinants. Evaluations had been performed on field-grown leaves in a single 12 months. The QTL for ribbon trichome density on adaxial vein and adaxial leaf and easy density on abaxial vein was high-quality mapped to 12.63-13.38 Mbp (747 kb) on chromosome 1. We discovered variations of MN1264 and MN1246 at candidate genes NAC transcription issue 29, EF-hand protein, and MYB140 in this area and three different surrounding candidate genes proposed beforehand.
Even although no robust relationship between foliar phylloxera resistance and trichome density was discovered, this examine validated and high-quality mapped a main QTL for trichome density utilizing a cold-hardy hybrid grape inhabitants and shed gentle on a few candidate genes which have implications for various breeding applications.
A singular partial anomalous pulmonary venous return in mixture with different uncommon malformations akin to annular pancreas and a persistent umbilical vein was found in a feminine Caucasian cadaver throughout an anatomical dissection on the Paracelsus Medical University in Nuremberg, Germany. The pulmonary anomaly comprised of the aberrant left superior pulmonary vein connecting the superior lobe of the left lung with the left brachiocephalic vein ensuing in a left to proper shunt.
An annular pancreas with none indicators of possible symptom inflicting duodenal compression was moreover discovered. To full the constellation of malformations, a persistent umbilical vein connecting to the inferior department of the extrahepatic left portal vein working in the spherical ligament fissure of the liver was additionally noticed. This uncommon constellation of malformations has been illustrated and totally mentioned with the at the moment obtainable literature to develop a speculation for the genetic and developmental background.
The origin of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the topic of many hypotheses. One of them, proposed by Segreto and Deigin, assumes synthetic chimeric development of SARS-CoV-2 from a spine of RaTG13-like CoV and receptor binding area (RBD) of a pangolin MP789-like CoV, adopted by serial cell or animal passage. Here we present that this speculation depends on incorrect or weak assumptions, and doesn’t agree with the outcomes of comparative genomics evaluation.
The genetic divergence between SARS-CoV-2 and each its proposed ancestors is simply too excessive to have accrued in a lab, given the timeframe of a number of years. Furthermore, comparative evaluation of S-protein gene sequences means that the RBD of SARS-CoV-2 most likely represents an ancestral non-recombinant variant. These and different arguments considerably weaken the speculation of a laboratory origin for SARS-CoV-2, whereas the speculation of a pure origin is according to all obtainable genetic and experimental knowledge.
The emergence of the genetic counseling occupation has allowed laypeople to grasp and profit from organic advances, and to make vital selections about their utility. The self-discipline of genetic counseling has been criticized from its very starting, in specific as a result of of its early affiliation with the eugenics motion. This paper presents a vital and reflective overview of how genetic counseling is implicitly embedded in the historical past of eugenics but additionally counteracts previous eugenic practices and concepts. After World War II, makes an attempt had been made to distance genetic counseling from eugenics.
The first definition of genetic counseling didn’t place this area as a medical encounter however “as a form of genetic social work aimed primarily to offer individuals with an understanding of their household’s genetics issues.” This strategy was a response to the genetic and social evolutionary concepts that knowledgeable eugenic theories through the first half of the 20th century. Professionals engaged in genetic counseling through the 1940s and1950s rejected eugenic practices, however there was nonetheless assist for eugenics’ objectives of enhancing heredity and eliminating illness. From the 1960s, genetic counseling underwent professionalization alongside feminization and a definition of core values. Among these values had been nondirectiveness counseling and the autonomy of the counselee.
JAG-1, scrambled |
|||
TP1686-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: JAG-1, scrambled |
JAG-1, scrambled |
|||
MBS5789393-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human NEP1-40 of Nogo-66 peptide, Scrambled peptide control for NEP140, >95% pure |
|||
NEP140-115 | Alpha Diagnostics | 100 ug | EUR 343.2 |
Human NEP1-40 of Nogo-66 peptide Scrambled peptide control for NEP140 >95% pure |
|||
NEP140-115-1000 | Alpha Diagnostics | 1000 ug | EUR 927.6 |
LL-37 scrambled peptide |
|||
HY-P1513 | MedChemExpress | 1mg | EUR 418.8 |
LL-37 scrambled peptide |
|||
TP1825-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: LL-37 scrambled peptide |
LL-37 scrambled peptide |
|||
TP1825-1g | TargetMol Chemicals | 1g | Ask for price |
Description: LL-37 scrambled peptide |
LL-37 scrambled peptide |
|||
TP1825-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: LL-37 scrambled peptide |
LL-37 scrambled peptide |
|||
TP1825-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: LL-37 scrambled peptide |
LL-37 scrambled peptide |
|||
TP1825-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: LL-37 scrambled peptide |
LL-37 scrambled peptide |
|||
MBS5763833-1mg | MyBiosource | 1mg | EUR 260 |
LL-37 scrambled peptide |
|||
MBS5763833-5mg | MyBiosource | 5mg | EUR 760 |
LL-37 scrambled peptide |
|||
MBS5763833-5x5mg | MyBiosource | 5x5mg | EUR 3265 |
Scrambled TRAP Fragment Peptide |
|||
20-abx265858 | Abbexa |
|
|
Scrambled TRAP Fragment Peptide |
|||
abx265858-200tests | Abbexa | 200 tests | EUR 225 |
Scrambled TRAP Fragment Peptide |
|||
abx265858-500tests | Abbexa | 500 tests | EUR 312.5 |
Scrambled-peptide Knockdown Control Cell Line Expressing Dendra2 |
|||
T6521 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
JAG-1, scrambled TFA(402941-23-5 free base) |
|||
TP1686L-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: JAG-1, scrambled TFA(402941-23-5 free base) |
JAG-1, scrambled TFA(402941-23-5 free base) |
|||
TP1686L-1g | TargetMol Chemicals | 1g | Ask for price |
Description: JAG-1, scrambled TFA(402941-23-5 free base) |
JAG-1, scrambled TFA(402941-23-5 free base) |
|||
TP1686L-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: JAG-1, scrambled TFA(402941-23-5 free base) |
JAG-1, scrambled TFA(402941-23-5 free base) |
|||
TP1686L-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: JAG-1, scrambled TFA(402941-23-5 free base) |
JAG-1, scrambled TFA(402941-23-5 free base) |
|||
TP1686L-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: JAG-1, scrambled TFA(402941-23-5 free base) |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
MBS5765434-10mg | MyBiosource | 10mg | EUR 335 |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
MBS5765434-25mg | MyBiosource | 25mg | EUR 545 |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
MBS5765434-2mg | MyBiosource | 2mg | EUR 210 |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
MBS5765434-50mg | MyBiosource | 50mg | EUR 780 |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
MBS5765434-5mg | MyBiosource | 5mg | EUR 255 |
sgp91 ds-tat Peptide 2, scrambled |
|||
TP1585-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: sgp91 ds-tat Peptide 2, scrambled |
sgp91 ds-tat Peptide 2, scrambled |
|||
TP1585-1g | TargetMol Chemicals | 1g | Ask for price |
Description: sgp91 ds-tat Peptide 2, scrambled |
sgp91 ds-tat Peptide 2, scrambled |
|||
TP1585-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: sgp91 ds-tat Peptide 2, scrambled |
sgp91 ds-tat Peptide 2, scrambled |
|||
TP1585-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: sgp91 ds-tat Peptide 2, scrambled |
sgp91 ds-tat Peptide 2, scrambled |
|||
TP1585-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: sgp91 ds-tat Peptide 2, scrambled |
sgp91 ds-tat Peptide 2, scrambled |
|||
MBS5789300-INQUIRE | MyBiosource | INQUIRE | Ask for price |
3-D Life Scrambled RGD Peptide |
|||
09-P-003 | Cellendes | 1 µmol | EUR 107 |
3-D Life Scrambled RGD Peptide |
|||
P11-3 | Cellendes | 3x 1 µmol | EUR 289 |
Scrambled shRNA Control THP-1 Cell Line (With GFP) -Polyclone |
|||
T9790 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
PGMtide Control Peptide |
|||
040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
L201 pLVPTH2- tTR- KRAB- Cerulean- scrambled- shRNA- Control |
|||
PVT11122 | Nova Lifetech | 2ug | EUR 215 |
Scrambled Cathelicidin antimicrobial peptide 18 |
|||
SB010 | Smartox Biotechnology | 1 | EUR 134.41 |
Description: Scrambled LL-37 has the same peptide sequence as LL-37 but loses helixforming property.Scrambled LL-37 can be used as a negative control of LL-37 studies. |
JAG-1 Protein Active Peptide Fragment |
|||
080-11 | PHOENIX PEPTIDE | 100 μg | EUR 129.6 |
PGMtide Control Peptide - Cy3 Labeled |
|||
FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Control Peptide - FAM Labeled |
|||
FG-040-70A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
PGMtide Control Peptide - Biotin Labeled |
|||
B-040-70 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
PGMtide Control Peptide - Rhodamine Labeled |
|||
FR-040-70 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Human, mouse, rat connexin 43 and 37 scrambled peptide (GAP27 domain) |
|||
Cx2704-PS-1 | Alpha Diagnostics | 1 mg | EUR 315.6 |
Human, mouse, rat connexin 43 and 37 scrambled peptide (GAP27 domain) |
|||
Cx2704-PS-5 | Alpha Diagnostics | 5 mg | EUR 927.6 |
Human, mouse, rat connexin 37/40 hemi-channel Scrambled peptide (GAP26 domain) |
|||
Cx2602-PS-1 | Alpha Diagnostics | 1 mg | EUR 343.2 |
Human, mouse, rat connexin 37/40 hemi-channel Scrambled peptide (GAP26 domain) |
|||
Cx2602-PS-5 | Alpha Diagnostics | 5 mg | EUR 927.6 |
ZIP (SCRAMBLED) |
|||
A8830-1 | ApexBio | 1 mg | EUR 74 |
Description: PKMζ inhibitor |
PADRE scrambled |
|||
SB084 | Smartox Biotechnology | 1 | EUR 81.81 |
Description: SB-peptide offers the scrambled version of PADRE peptide. AAATLWKAAKFVA can be used as a negative control of PADRE peptide studies.SB-peptide offers also PADRE peptide (see section PADRE peptide).PADRE peptide: Pan HLA DR-binding epitope is a universal peptide that activates antigen specific-CD4+ T cells which can be used as an agonist adjuvant in immunotherapeutic vaccine development. Pan HLA DR-binding epitope has been proposed as a carrier epitope suitable for use in the development of synthetic and recombinant vaccines. It has been demonstrated that PADRE may be an universal approach to control tumor cells. Moreover, PADRE is also used in research about an immunosense approach to develop a base for development of vaccines against toxoplasmosis to protect person with HLA-A*03 type. Pan HLA DR-binding epitope can be also used as tool to study the autoreactive T cell response. |
Scrambled 10Panx |
|||
A2701-1 | ApexBio | 1 mg | EUR 40 |
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
Scrambled 10Panx |
|||
A2701-10 | ApexBio | 10 mg | EUR 144 |
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
Scrambled 10Panx |
|||
A2701-25 | ApexBio | 25 mg | EUR 320 |
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
Scrambled 10Panx |
|||
A2701-5 | ApexBio | 5 mg | EUR 80 |
Description: Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
Scrambled 10Panx |
|||
MBS3840702-10mg | MyBiosource | 10mg | EUR 235 |
Scrambled 10Panx |
|||
MBS3840702-25mg | MyBiosource | 25mg | EUR 430 |
Scrambled 10Panx |
|||
MBS3840702-5mg | MyBiosource | 5mg | EUR 165 |
Scrambled 10Panx |
|||
MBS3840702-5x25mg | MyBiosource | 5x25mg | EUR 1920 |
LL-37 (scrambled) |
|||
4099707.05 | Bachem | 0.5 mg | EUR 195.51 |
LL-37 (scrambled) |
|||
4099707.1 | Bachem | 1 mg | EUR 317.94 |
LL-37 (scrambled) |
|||
H-7886.0500 | Bachem | 0.5mg | EUR 339.6 |
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net |
LL-37 (scrambled) |
|||
H-7886.1000 | Bachem | 1.0mg | EUR 529.2 |
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net |
ZIP (SCRAMBLED) Acetate |
|||
T22175L-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: ZIP (SCRAMBLED) Acetate |
ZIP (SCRAMBLED) Acetate |
|||
T22175L-1g | TargetMol Chemicals | 1g | Ask for price |
Description: ZIP (SCRAMBLED) Acetate |
ZIP (SCRAMBLED) Acetate |
|||
T22175L-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: ZIP (SCRAMBLED) Acetate |
ZIP (SCRAMBLED) Acetate |
|||
T22175L-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: ZIP (SCRAMBLED) Acetate |
ZIP (SCRAMBLED) Acetate |
|||
T22175L-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: ZIP (SCRAMBLED) Acetate |
ZIP (SCRAMBLED) Acetate |
|||
MBS5773250-1mg | MyBiosource | 1mg | EUR 190 |
ZIP (SCRAMBLED) Acetate |
|||
MBS5773250-2mg | MyBiosource | 2mg | EUR 235 |
ZIP (SCRAMBLED) Acetate |
|||
MBS5773250-5mg | MyBiosource | 5(mg | EUR 300 |
Scrambled TRAP Fragment |
|||
5-01910 | CHI Scientific | 4 x 5mg | Ask for price |
Scrambled TRAP Fragment |
|||
T38743-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: Scrambled TRAP Fragment |
Scrambled TRAP Fragment |
|||
T38743-1g | TargetMol Chemicals | 1g | Ask for price |
Description: Scrambled TRAP Fragment |
Scrambled TRAP Fragment |
|||
T38743-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: Scrambled TRAP Fragment |
Scrambled TRAP Fragment |
|||
T38743-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: Scrambled TRAP Fragment |
Scrambled TRAP Fragment |
|||
T38743-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: Scrambled TRAP Fragment |
Scrambled TRAP Fragment |
|||
MBS5799340-5mg | MyBiosource | 5(mg | EUR 915 |
Scrambled TRAP Fragment |
|||
MBS5799340-5x5mg | MyBiosource | 5x5(mg | EUR 3970 |
Scrambled TRAP Fragment |
|||
MBS8247030-10mg | MyBiosource | 10mg | EUR 560 |
Scrambled TRAP Fragment |
|||
MBS8247030-1mg | MyBiosource | 1mg | EUR 225 |
Scrambled TRAP Fragment |
|||
MBS8247030-5mg | MyBiosource | 5mg | EUR 400 |
Scrambled TRAP Fragment |
|||
MBS8247030-5x10mg | MyBiosource | 5x10mg | EUR 2435 |
OVA 257-264 scrambled |
|||
SB073 | Smartox Biotechnology | 1 | EUR 81.81 |
Description: SB-peptide offers the scrambled version of OVA 257-264. FILKSINE can be used as a negative control of OVA 257-264 studies.SB-peptide offers also OVA 257-264 (see section OVA 257-264).Ovalbumin protein:OVA 257-264 (H-2Kb) is an epitope of interest of the egg white albumen, ovalbumin. Ovalbumin is a glycoprotein that is sufficiently large and complex to be mildly immunogenic. Indeed, it has been demonstrated that Ovalbumin contains B-cell epitopes which are recognized by specific IgE antibodies and CD4 T cell epitopes restricted by the MHC I-Ad molecule in mice and by HLA-D molecule in human.Applications of OVA 257-264:OVA 257-264 is used to stimulate T cells in PBMCs and to quantify peptide epitope specificity and IFN-γ releasing effector cells by ELISPOT assay. OVA 257-264 is also used to test new adjuvant in immunotherapeutic vaccine development. OVA 257-264 can form a stable hydrogel and stimulate a immune response. This reaction seems to be linked with OVA 257-264 property to self-assemble into a hydrogel. Sequence:C45H74N10013 |
Neuropeptide Y (scrambled) |
|||
B7530-1 | ApexBio | 1 mg | EUR 486 |
Description: Scrambled Neuropeptide Y (scNPY) was similarly synthesized and contains the same amino acids as NPY, but scNPY is in a random sequence, it was used as a control in the research in NPY [1]. The sequence of scNPY is SKPQRDANREPTRYAIYDYSNPDIELHYLRPAYALG-NH2 [2]. |
Neuropeptide Y (scrambled) |
|||
TP2194-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: Neuropeptide Y (scrambled) |
Neuropeptide Y (scrambled) |
|||
TP2194-1g | TargetMol Chemicals | 1g | Ask for price |
Description: Neuropeptide Y (scrambled) |
Neuropeptide Y (scrambled) |
|||
TP2194-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: Neuropeptide Y (scrambled) |
Neuropeptide Y (scrambled) |
|||
TP2194-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: Neuropeptide Y (scrambled) |
Neuropeptide Y (scrambled) |
|||
TP2194-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: Neuropeptide Y (scrambled) |
Neuropeptide Y (scrambled) |
|||
MBS5764161-1mg | MyBiosource | 1mg | EUR 625 |
Neuropeptide Y (scrambled) |
|||
MBS5764161-5x1mg | MyBiosource | 5x1mg | EUR 2655 |
Amyloid β-Protein (1-42) (scrambled) |
|||
4064853.05 | Bachem | 0.5 mg | EUR 317.94 |
Amyloid β-Protein (1-42) (scrambled) |
|||
4064853.1 | Bachem | 1 mg | EUR 432.6 |
Amyloid b-Protein (1-42) (scrambled) |
|||
H-7406.0500 | Bachem | 0.5mg | EUR 529.2 |
Description: Sum Formula: C203H311N55O60S; CAS# [1678415-52-5] net |
Amyloid b-Protein (1-42) (scrambled) |
|||
H-7406.1000 | Bachem | 1.0mg | EUR 706.8 |
Description: Sum Formula: C203H311N55O60S; CAS# [1678415-52-5] net |
Amyloid b-Protein (1-40) (scrambled) |
|||
H-7408.0500 | Bachem | 0.5mg | EUR 402 |
Description: Sum Formula: C194H295N53O58S; CAS# [1678415-68-3] net |
Amyloid b-Protein (1-40) (scrambled) |
|||
H-7408.1000 | Bachem | 1.0mg | EUR 727.2 |
Description: Sum Formula: C194H295N53O58S; CAS# [1678415-68-3] net |
Mouse Lipin-1 Control/blocking peptide control/blocking peptide #1 |
|||
LPN11-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
MAGE-A p248V9 scrambled |
|||
SB080 | Smartox Biotechnology | 1 | EUR 93.5 |
Description: SB-peptide offers the scrambled version of MAGE-A p248V9. RQYVELPYV can be used as a negative control of MAGE-A p248V9 studies.SB-peptide offers also MAGE-A p248V9 (see section MAGE-A p248V9)).MAGE-A protein:MAGE-A p248V9, also kwon as multi-MAGE-A (YLEYRQVPV) is an epitope of Melanoma Antigen Gene expressed by tumors of different histological types and is a Cancer/Testis Antigens (CTA). Type of MAGE-A expressed in tumors cells varies according to the type of tumor. Targeting epitopes shared by all MAGE-A antigens would be interest in immunotherapy against a broad spectrum of cancers. Applications of MAGE-A p248V9 (multi-MAGE-A) :MAGE-A p248V9 is very useful because it could generate an HLA-A*02:01-restricted CTL response and shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10 and -A12. MAGE-A p248V9 is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay.Sequence : RQYVELPYV |
Human MDM2 siRNA (Scrambled) |
|||
abx941274-150g | Abbexa | 150 µg | EUR 450 |
Human MDM2 siRNA (Scrambled) |
|||
abx941274-300g | Abbexa | 300 µg | EUR 612.5 |
PAR-2 (1-6) amide (human) (scrambled) |
|||
H-6428.0025 | Bachem | 25.0mg | EUR 385.2 |
Description: Sum Formula: C28H54N8O7; CAS# [1348395-60-7] net |
PAR-2 (1-6) amide (human) (scrambled) |
|||
H-6428.0100 | Bachem | 100.0mg | EUR 1082.4 |
Description: Sum Formula: C28H54N8O7; CAS# [1348395-60-7] net |
Melan-A (26-35) scrambled |
|||
SB081 | Smartox Biotechnology | 1 | EUR 64.28 |
Description: SB-peptide offers the scrambled version of Melan-A/MART-1 (26-35). AIEIAGGLTV can be used as a negative control of Melan-A/MART-1 (26-35) studies.SB-peptide offers also Melan-A/MART-1 (26-35) (see section Melan-A/MART-1 (26-35)).Native Melan-A (26-35) decapepetide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas1.The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide1. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity1.It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide. Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide1. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min)1.Sequence : AIEIAGGLTV |
MAGE-A2 (157-166) scrambled |
|||
SB082 | Smartox Biotechnology | 1 | EUR 93.5 |
Description: SB-peptide offers the scrambled version of MAGE-A2 (157-166). VLVYFQEIGL can be used as a negative control of MAGE-A2 (157-166) studies.SB-peptide offers also MAGE-A2 (157-166) (see section MAGE-A2 (157-166)).MAGE-A2 protein: MAGE-A2 (157-166) is an epitope of Melanoma Antigen Gene A2 and is one of the most Cancer-Testis Antigens (CTA) overexpressed in tumors of different histological types, such as prostate cancer. Type of MAGE-A expressed in tumors cells varies according to the type of tumor. The expression of MAGE-A2 causes the proliferation of prostate cancer cells and decreases the chemosensitivity. Applications of MAGE-A2 (157-166):MAGE-A2 (157-166) is used to stimulate specific immune response, cytotoxic T cell response and to analyze the cytokine production in PBMCs by ELISPOT assay. In transgenic mouse, it has been demonstrated that MAGE-A2 (157-166) was capable of eliciting a CTL response presented by HLA-A*02:01 molecules. MAGE-A2 (157-166) has been reported to elicit CTL that could lyse tumor cell expressing both HLA-A*02:01 and MAGE-A2 by stimulation of peripheral blood mononuclear cells (PBMCs) with MAGE-A2 (157-166).Sequence : VLVYFQEIGL |
MAGE-A1 (278-286) scrambled |
|||
SB083 | Smartox Biotechnology | 1 | EUR 93.5 |
Description: SB-peptide offers the scrambled version of MAGE-A1 (278-286). ELIVKVYKV can be used as a negative control of MAGE-A1 (278-286) studies.SB-peptide offers also MAGE-A1 (278-286) (see section MAGE-A1 (278-286)).MAGE-A1 protein:MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells. Applications of MAGE-A1 (278-286): MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.Sequence : ELIVKVYKV |
Human EGFRviii siRNA (Scrambled) |
|||
abx941279-150g | Abbexa | 150 µg | EUR 450 |
Human EGFRviii siRNA (Scrambled) |
|||
abx941279-300g | Abbexa | 300 µg | EUR 612.5 |
Mouse Lipin-2 Control/blocking peptide control/blocking peptide #1 |
|||
LPN21-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Mouse Lipin-3 Control/blocking peptide control/blocking peptide #1 |
|||
LPN31-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
5-FAM-LL-37 (scrambled) |
|||
4099708.05 | Bachem | 0.5 mg | EUR 335.9 |
5-FAM-LL-37 (scrambled) |
|||
4099708.1 | Bachem | 1 mg | EUR 577.5 |
5-FAM-LL-37 (scrambled) |
|||
H-7888.0500 | Bachem | 0.5mg | EUR 559.2 |
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net |
5-FAM-LL-37 (scrambled) |
|||
H-7888.1000 | Bachem | 1.0mg | EUR 931.2 |
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net |
Scrambled sgRNA CRISPR Lentivector |
|||
K018 | ABM | 1.0 ug | EUR 184.8 |
Amyloid beta-Protein (Human, 1-40) (Scrambled) |
|||
MBS407587-01mg | MyBiosource | 0.1mg | EUR 215 |
Amyloid beta-Protein (Human, 1-40) (Scrambled) |
|||
MBS407587-5x01mg | MyBiosource | 5x0.1mg | EUR 915 |
Amyloid beta-Protein (Human, 1-42) (Scrambled) |
|||
MBS407588-01mg | MyBiosource | 0.1mg | EUR 320 |
Amyloid beta-Protein (Human, 1-42) (Scrambled) |
|||
MBS407588-5x01mg | MyBiosource | 5x0.1mg | EUR 1385 |
Teplow's Amyloid β-Protein (1-40) (scrambled II) |
|||
4104167.01 | Bachem | 0.1 mg | EUR 86.52 |
Teplow's Amyloid β-Protein (1-40) (scrambled II) |
|||
4104167.05 | Bachem | 0.5 mg | EUR 299.99 |
Teplow's Amyloid β-Protein (1-42) (scrambled II) |
|||
4104168.05 | Bachem | 0.5 mg | EUR 299.99 |
Teplow's Amyloid β-Protein (1-42) (scrambled II) |
|||
4104168.1 | Bachem | 1 mg | EUR 450.56 |
5-FAM-Amyloid β-Protein (1-42) (scrambled) |
|||
4099694.01 | Bachem | 0.1 mg | EUR 99.96 |
5-FAM-Amyloid β-Protein (1-42) (scrambled) |
|||
4099694.05 | Bachem | 0.5 mg | EUR 359.52 |
5-FAM-Amyloid b-Protein (1-42) (scrambled) |
|||
H-7836.0100 | Bachem | 0.1mg | EUR 192 |
Description: Sum Formula: C224H321N55O66S |
5-FAM-Amyloid b-Protein (1-42) (scrambled) |
|||
H-7836.0500 | Bachem | 0.5mg | EUR 594 |
Description: Sum Formula: C224H321N55O66S |
Teplow's Amyloid b-Protein (1-40) (scrambled II) |
|||
H-8278.0100 | Bachem | 0.1mg | EUR 170.4 |
Description: Sum Formula: C194H295N53O58S |
Teplow's Amyloid b-Protein (1-40) (scrambled II) |
|||
H-8278.0500 | Bachem | 0.5mg | EUR 501.6 |
Description: Sum Formula: C194H295N53O58S |
Teplow's Amyloid b-Protein (1-42) (scrambled II) |
|||
H-8282.0500 | Bachem | 0.5mg | EUR 501.6 |
Description: Sum Formula: C203H311N55O60S |
Teplow's Amyloid b-Protein (1-42) (scrambled II) |
|||
H-8282.1000 | Bachem | 1.0mg | EUR 734.4 |
Description: Sum Formula: C203H311N55O60S |
Biotinyl-εAhx-LL-37 (scrambled) |
|||
4099709.05 | Bachem | 0.5 mg | EUR 326.97 |
Biotinyl-εAhx-LL-37 (scrambled) |
|||
4099709.1 | Bachem | 1 mg | EUR 555.03 |
Biotinyl-eAhx-LL-37 (scrambled) |
|||
H-7896.0500 | Bachem | 0.5mg | EUR 542.4 |
Description: Sum Formula: C221H365N63O56S; CAS# [2022972-72-9] net |
Biotinyl-eAhx-LL-37 (scrambled) |
|||
H-7896.1000 | Bachem | 1.0mg | EUR 896.4 |
Description: Sum Formula: C221H365N63O56S; CAS# [2022972-72-9] net |
NY-ESO-1 (157-165) C165V scrambled (MSILWQLVT) |
|||
SB079 | Smartox Biotechnology | 1 | EUR 93.5 |
Description: SB-peptide offers the scrambled MSILWQLVT peptide that can be used as a negative control of NY-ESO-1 (157-165) C165V variant epitope studies.SB-peptide also offers NY-ESO-1 (157-165) C165V (see section NY-ESO-1 (157-165) C165V). HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) native SLLMWITQC peptide, whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) C165V peptide application Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein, including SLLMWITQC, that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members, its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.SB-peptide offers the scrambled MSILWQLVT peptide that can be used as a negative control of NY-ESO-1 (157-165) C165V variant epitope studies.SB-peptide also offers NY-ESO-1 (157-165) C165V (see section NY-ESO-1 (157-165) C165V). HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) native SLLMWITQC peptide, whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) C165V peptide application Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein, including SLLMWITQC, that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members, its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope, specificity, and cytokine production, like IFN-γ, SLLMWITQV variant peptide was used, as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover, SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.SB-PEPTIDE also offers NY-ESO-1 (157-165) native peptide, as well as Biotin-NY-ESO-1 (157-165) C165V.In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope, specificity, and cytokine production, like IFN-γ, SLLMWITQV variant peptide was used, as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover, SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.SB-PEPTIDE also offers NY-ESO-1 (157-165) native peptide, as well as Biotin-NY-ESO-1 (157-165) C165V. |
Human Canonical EGFR siRNA (Scrambled) |
|||
abx941277-150g | Abbexa | 150 µg | EUR 450 |
Human Canonical EGFR siRNA (Scrambled) |
|||
abx941277-300g | Abbexa | 300 µg | EUR 612.5 |
Scrambled sgRNA CRISPR/Cas9 THP-1 Cell Line |
|||
T9700 | ABM | 1x10^6 cells / 1.0 ml | EUR 3950 |
Tide Fluor 2-LL-37 (scrambled) |
|||
H-8288.0100 | Bachem | 0.1mg | EUR 374.4 |
Description: Sum Formula: C205H340N60O53+dye |
Tide Fluor 2-LL-37 (scrambled) |
|||
H-8288.0500 | Bachem | 0.5mg | EUR 1220.4 |
Description: Sum Formula: C205H340N60O53+dye |
Prion Protein (106-126) (human) (scrambled) |
|||
4033124.05 | Bachem | 0.5 mg | EUR 187.64 |
Prion Protein (106-126) (human) (scrambled) |
|||
4033124.1 | Bachem | 1 mg | EUR 299.99 |
The darkish shadow of Nazi ideology and different eugenic practices, makes an attempt to make use of the historic duty of geneticists, and the dynamic medical, social, political, and academic adjustments of the 1960s and 1970s helped to border approaches and delineate the objectives and limits of the brand new occupation of “genetic counseling.”